FDA Expands Abemaciclib Use in High-Risk Early Breast Cancer
Certain patients with high-risk early breast cancer can now receive abemaciclib (Verzenio) without needing Ki-67 testing.
Medscape Medical News
source https://www.medscape.com/viewarticle/989139?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/989139?src=rss
Comments
Post a Comment